Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
04:39pm, Monday, 09'th Aug 2021
-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth
Catalyst Pharmaceutical (CPRX) Reports Next Week: What Awaits?
04:45pm, Monday, 02'nd Aug 2021
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, d
Do Earnings Reports Matter for Biotech Stocks?
06:19am, Saturday, 24'th Jul 2021
Yes, but it often doesn't have much to do with revenue.
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
08:03am, Monday, 19'th Jul 2021
CORAL GABLES, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licens
Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns
11:35am, Thursday, 15'th Jul 2021
Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer
08:03am, Tuesday, 06'th Jul 2021
CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
08:03am, Tuesday, 29'th Jun 2021
CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®
04:30pm, Monday, 28'th Jun 2021
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada
Catalyst Pharmaceuticals: Undervalued Cash Flow Generator With High Probability Of Outperformance
09:23am, Monday, 31'st May 2021
Catalyst Pharmaceuticals is a small cap biopharma company with a highly profitable ultra-orphan drug, Firdapse, for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS). Firdapse wa
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
08:03am, Wednesday, 19'th May 2021
CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals' (CPRX) CEO Patrick McEnany on Q1 2021 Results - Earnings Call Transcript
01:51pm, Tuesday, 11'th May 2021
Catalyst Pharmaceuticals' (CPRX) CEO Patrick McEnany on Q1 2021 Results - Earnings Call Transcript
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
10:31am, Tuesday, 11'th May 2021
Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.
